Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This was a retrospective study of 238 patients, including 92 with type-2 DM (DM2) and 11 with type-1 DM (DM1), having routine whole body FDG PET/CT.Patients with lymphoma were excluded.
|
31769591 |
2020 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparisons of CT features and <sup>18</sup>F-FDG metabolic indices between benign and malignant entities, as well as among primary and secondary malignancies and lymphoma, were performed.
|
31807883 |
2020 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG PET/CT detected unsuspected extraocular lymphoma involvement in 14% of the patients.
|
31754896 |
2019 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Predictions of outcome after first-line treatment for DLBCL were surprisingly good when left to the unsupervised, subjective judgment of experienced readers of lymphoma 18F-FDG-PET/CT.
|
31054023 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interim and posttreatment sequential FDG PET/CT scans revealed a residual splenic mass showing markedly intense FDG uptake suspected of a residual viable lymphoma.
|
30985428 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although <sup>18</sup>F-FDG has proved useful in the management of patients with lymphoma, the specificity of <sup>18</sup>F-FDG uptake has been critically questioned, and is not without flaws.
|
31058154 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impact of early fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) status on survival after allogeneic transplantation for lymphoma is poorly reported.
|
30481598 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphadenopathy Due to Kimura's Disease Mimicking Lymphoma on FDG PET/CT.
|
30688747 |
2019 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Burkitt's lymphoma is a lymphoma with unclear metabolic behavior at 18F-FDG-PET/CT and no validated criteria in treatment evaluation and prediction of outcome exist.
|
29966473 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
[<sup>18</sup>F]FB-GAcDb immunoPET was further evaluated in a disseminated lymphoma (A20-hCD20) syngeneic for hCD20TM and compared to [<sup>18</sup>F]FDG PET.
|
30456475 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET/CT also detected an unsuspected synchronous lymphoma in 1 patient.
|
30237211 |
2019 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Except for SUVmin (<i>p</i>=0.971), the averages of FDG uptake metrics of lymphoma were significantly higher than those of carcinoma (<i>p</i> ≤ 0.001), with the following median values: SUV<sub>mean</sub>, 4.75 versus 2.38 g/ml (<i>P</i> < 0.001); SUV<sub>std</sub>, 2.04 versus 0.88 g/ml (<i>P</i>=0.001); SUV<sub>max</sub>, 10.69 versus 4.76 g/ml (<i>P</i>=0.001); SUV<sub>peak</sub>, 9.15 versus 2.78 g/ml (<i>P</i> < 0.001); TLG, 42.24 versus 9.90 (<i>P</i> < 0.001).
|
30930700 |
2019 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We prospectively evaluated 76 ALPS/ALPS-like patients including FS-7-associated surface antigen (FAS) germline mutation with (n = 4) and without lymphoma (n = 50), FAS-somatic (n = 6), ALPS-unknown (n = 6), and others (n = 10) who underwent FDG PET.
|
31693620 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this case, we aim to highlight this interesting FDG PET/CT imaging finding, which can serve as a clue allowing one to strongly suggest lymphoma as the leading diagnosis.
|
30688737 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
18F-FDG-PET/CT has become a standard for assessing treatment response in patients with lymphoma.
|
30284376 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
F-FDG PET/CT lymphatic node hypermetabolism is not specific to lymphoma, particularly in immunocompromised patients.
|
31107755 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG uptake in the lymph nodes was observed in 53.3% of the patients with lymphoma and 43.3% of the patients without lymphoma, with no difference in the number of sites, uptake pattern, or mean SUVmax.
|
30615273 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study.
|
30849131 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG PET/CT) is currently the criterion standard of lymphoma imaging and recommended through all stages of Hodgkin lymphoma management.
|
30247256 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> The identification of additional lesions outside the R-FOV (eyes to thighs) using <sup>18</sup>F-FDG PET/CT has no impact in the definition of the clinical stage of disease and minimal impact in the treatment definition of patients with pediatric lymphoma.
|
30683766 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
F-FDG PET/CT lymphatic node hypermetabolism is not specific to lymphoma, particularly in immunocompromised patients.
|
31274617 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 18F-FDG positron-emission tomography (PET) and contrast-enhanced computerised tomography (CECT) data of all relapsed or refractory HL treated at Gustave Roussy, Villejuif, France, from 2013 to 2015 were retrospectively reviewed according to the International Harmonisation Project Cheson 2014 criteria and the LYmphoma Response to Immunomodulatory therapy Criteria (LYRIC).
|
29360605 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
F-FDG PET/CT showed hypermetabolic foci in the liver, spleen, and bone marrow, as well as multiple FDG-avid lymph nodes, which were highly suggestive of lymphoma.
|
29215415 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG PET/CT has optimum negative predictive value compared with BMB in detection of bone marrow infiltrations in pediatric lymphoma with upstaging cases missed with BMB.
|
30358625 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whole-body MRI versus <sup>18</sup>F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis.
|
29950864 |
2018 |